Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.

Balõtšev R, Haring L, Koido K, Leping V, Kriisa K, Zilmer M, Vasar V, Piir A, Lang A, Vasar E.

Early Interv Psychiatry. 2019 Feb;13(1):101-109. doi: 10.1111/eip.12457. Epub 2017 Jul 18.

PMID:
28719155
2.

Antipsychotic Treatment Reduces Indices of Oxidative Stress in First-Episode Psychosis Patients.

Kriisa K, Haring L, Vasar E, Koido K, Janno S, Vasar V, Zilmer K, Zilmer M.

Oxid Med Cell Longev. 2016;2016:9616593. doi: 10.1155/2016/9616593. Epub 2016 Jul 27.

3.

Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index.

Haring L, Koido K, Vasar V, Leping V, Zilmer K, Zilmer M, Vasar E.

Schizophr Res. 2015 Dec;169(1-3):22-29. doi: 10.1016/j.schres.2015.08.027. Epub 2015 Sep 11.

PMID:
26364730
4.

Polymorphisms of IKBKE gene are associated with major depressive disorder and panic disorder.

Traks T, Koido K, Balõtšev R, Eller T, Kõks S, Maron E, Tõru I, Shlik J, Vasar E, Vasar V.

Brain Behav. 2015 Apr;5(4):e00314. doi: 10.1002/brb3.314. Epub 2015 Feb 13.

5.

Associations between polymorphisms of LSAMP gene and schizophrenia.

Koido K, Janno S, Traks T, Parksepp M, Ljubajev Ü, Veiksaar P, Must A, Shlik J, Vasar V, Vasar E.

Psychiatry Res. 2014 Mar 30;215(3):797-8. doi: 10.1016/j.psychres.2014.01.016. Epub 2014 Jan 21.

PMID:
24491686
6.

A survey of parentally reported sleep health disorders in Estonian 8-9 year old children.

Vaher H, Kasenõmm P, Vasar V, Veldi M.

BMC Pediatr. 2013 Dec 4;13:200. doi: 10.1186/1471-2431-13-200.

7.

Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.

Tammiste A, Jiang T, Fischer K, Mägi R, Krjutškov K, Pettai K, Esko T, Li Y, Tansey KE, Carroll LS, Uher R, McGuffin P, Võsa U, Tšernikova N, Saria A, Ng PC, Eller T, Vasar V, Nutt DJ, Maron E, Wang J, Metspalu A.

J Psychopharmacol. 2013 Oct;27(10):915-20. doi: 10.1177/0269881113499829. Epub 2013 Aug 7.

PMID:
23926243
8.

The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.

Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J.

Eur Neuropsychopharmacol. 2013 Jul;23(7):645-52. doi: 10.1016/j.euroneuro.2012.08.011. Epub 2012 Aug 29.

PMID:
22939006
9.

Help-seeking for emotional problems in major depression : findings of the 2006 Estonian health survey.

Kleinberg A, Aluoja A, Vasar V.

Community Ment Health J. 2013 Aug;49(4):427-32. doi: 10.1007/s10597-012-9499-9. Epub 2012 Feb 4.

PMID:
22307317
10.

Diagnostic stability over 2 years in patients with acute and transient psychotic disorders.

Aadamsoo K, Saluveer E, Küünarpuu H, Vasar V, Maron E.

Nord J Psychiatry. 2011 Dec;65(6):381-8. doi: 10.3109/08039488.2011.565800. Epub 2011 Mar 28.

PMID:
21438790
11.

Gender differences in brain serotonin transporter availability in panic disorder.

Maron E, Tõru I, Hirvonen J, Tuominen L, Lumme V, Vasar V, Shlik J, Nutt DJ, Helin S, Någren K, Tiihonen J, Hietala J.

J Psychopharmacol. 2011 Jul;25(7):952-9. doi: 10.1177/0269881110389207. Epub 2010 Dec 8.

PMID:
21148024
12.

The past and the present of Estonian psychiatry.

Lehtmets A, Vasar V.

Nord J Psychiatry. 2010 Oct;64(5):350-2. doi: 10.3109/08039488.2010.520208. No abstract available.

PMID:
20840010
13.

Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.

Tõru I, Aluoja A, Võhma U, Raag M, Vasar V, Maron E, Shlik J.

Psychiatry Res. 2010 Jul 30;178(2):342-7. doi: 10.1016/j.psychres.2010.04.003. Epub 2010 May 14.

PMID:
20471107
14.

Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia.

Eller T, Aluoja A, Maron E, Vasar V.

Medicina (Kaunas). 2009;45(12):971-7.

15.

Obstructive sleep apnea syndrome (OSAS): Pathophysiology in Estonians.

Veldi M, Ani R, Vaher H, Eller T, Hion T, Aluoja A, Vasar V.

Pathophysiology. 2010 Jun;17(3):219-23. doi: 10.1016/j.pathophys.2010.01.001. Epub 2010 Feb 8.

PMID:
20116218
16.

Thyroid autoimmunity and treatment response to escitalopram in major depression.

Eller T, Metsküla K, Talja I, Maron E, Uibo R, Vasar V.

Nord J Psychiatry. 2010 Aug;64(4):253-7. doi: 10.3109/08039480903487533.

PMID:
20088751
17.

Evaluation of personality traits in panic disorder using Swedish universities Scales of Personality.

Võhma U, Aluoja A, Vasar V, Shlik J, Maron E.

J Anxiety Disord. 2010 Jan;24(1):141-6. doi: 10.1016/j.janxdis.2009.10.001.

PMID:
19883990
18.

Interleukin 10 family gene polymorphisms are not associated with major depressive disorder and panic disorder phenotypes.

Koido K, Eller T, Kingo K, Kõks S, Traks T, Shlik J, Vasar V, Vasar E, Maron E.

J Psychiatr Res. 2010 Apr;44(5):275-7. doi: 10.1016/j.jpsychires.2009.09.001. Epub 2009 Sep 27.

PMID:
19786281
19.

Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study.

Maron E, Eller T, Vasar V, Nutt DJ.

J Clin Psychiatry. 2009 Jul;70(7):1054-6. No abstract available.

PMID:
19653982
20.

The role of IL-2 and soluble IL-2R in depression and antidepressant response.

Eller T, Vasar V, Shlik J, Maron E.

Curr Opin Investig Drugs. 2009 Jul;10(7):638-43. Review.

PMID:
19579169

Supplemental Content

Loading ...
Support Center